Rexahn Pharma (RNN) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Rexahn Pharma (RNN) Tops Q1 EPS by 1c
May 11, 2015 9:02 AM EDT
ROCKVILLE, Md., May 11, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an update of its three clinical development programs and financial results for the quarter ending March 31, 2015.
"Rexahn remains very encouraged by the continued progress of the Supinoxin, RX-3117 and Archexin® clinical development programs. The additional data recently published with RX-3117 and Supinoxin has substantially increased the excitement around both of these programs by the scientific and clinical oncology communities. In these new studies RX-3117 demonstrated its ability to... More
